CoChat

The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses

Open access
Jongsma, Marlieke L.M., de Waard, Antonius A., Raaben, Matthijs, Zhang, Tao, Cabukusta, Birol, Platzer, René, Blomen, Vincent A., Xagara, Anastasia, Verkerk, Tamara, Bliss, Sophie, Kong, Xiangrui, Gerke, Carolin, Janssen, Lennert, Stickel, Elmer, Holst, Stephanie, Plomp, Rosina, Mulder, Arend, Ferrone, Soldano, Claas, Frans H.J., Heemskerk, Mirjam H.M., Griffioen, Marieke, Halenius, Anne, Overkleeft, Hermen, Huppa, Johannes B., Wuhrer, Manfred, Brummelkamp, Thijn R., Neefjes, Jacques, Spaapen, Robbert M. · 2021 · Immunity

Published version of a preprint

Cited by 108

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

SUMMARY HLA class I (HLA-I) glycoproteins drive immune responses by presenting antigens to cognate CD8+ T cells. This process is often hijacked by tumors and pathogens for immune evasion. Because options for restoring HLA-I antigen presentation are limited, we aimed to identify druggable HLA-I pathway targets. Using iterative genome-wide screens, we uncovered that the cell surface glycosphingolipid (GSL) repertoire determines effective HLA-I antigen presentation. We show that absence of the protease SPPL3 augmented B3GNT5 enzyme activity, resulting in upregulation of surface neolacto-series GSLs. These GSLs sterically impeded antibody and receptor interactions with HLA-I and diminished CD8+ T cell activation. Furthermore, a disturbed SPPL3-B3GNT5 pathway in glioma correlated with decreased patient survival. We show that the immunomodulatory effect could be reversed through GSL synthesis inhibition using clinically approved drugs. Overall, our study identifies a GSL signature that inhibits immune recognition and represents a potential therapeutic target in cancer, infection, and autoimmunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.11.003

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 106

  1. Achdout, 2008, Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins, J. Virol., 82, 8030, 10.1128/JVI.00870-08 · doi:10.1128/jvi.00870-08
  2. Allende, 2014, Simplifying complexity: genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function, Glycoconj. J., 31, 613, 10.1007/s10719-014-9563-5 · DOI
  3. Amir, 2011, Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific, Blood, 118, 6733, 10.1182/blood-2011-05-354787 · doi:10.1182/blood-2011-05-354787
  4. Anaya, 2016, OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs, PeerJ Comput. Sci., 2, e67, 10.7717/peerj-cs.67 · DOI · Paper page
  5. Andrews, 1989, Human cytomegalovirus induces stage-specific embryonic antigen 1 in differentiating human teratocarcinoma cells and fibroblasts, J. Exp. Med., 169, 1347, 10.1084/jem.169.4.1347 · DOI
  6. Anfossi, 2006, Human NK cell education by inhibitory receptors for MHC class I, Immunity, 25, 331, 10.1016/j.immuni.2006.06.013 · DOI · Paper page
  7. Barbosa, 1987, Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface expression and functional recognition, J. Exp. Med., 166, 1329, 10.1084/jem.166.5.1329 · doi:10.1084/jem.166.5.1329
  8. Berman, 2000, The Protein Data Bank, Nucleic Acids Res., 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
  9. Blees, 2017, Structure of the human MHC-I peptide-loading complex, Nature, 551, 525, 10.1038/nature24627 · DOI · Paper page
  10. Borges, 1997, A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules, J. Immunol., 159, 5192, 10.4049/jimmunol.159.11.5192 · DOI · Paper page
  11. Brameshuber, 2018, Monomeric TCRs drive T cell antigen recognition, Nat. Immunol., 19, 487, 10.1038/s41590-018-0092-4 · DOI
  12. Brockmann, 2017, Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling, Nature, 546, 307, 10.1038/nature22376 · DOI · Paper page
  13. Caffaro, 2006, Nucleotide sugar transporters of the Golgi apparatus: from basic science to diseases, Acc. Chem. Res., 39, 805, 10.1021/ar0400239 · DOI
  14. Carette, 2009, Haploid genetic screens in human cells identify host factors used by pathogens, Science, 326, 1231, 10.1126/science.1178955 · DOI · Paper page
  15. Catalaa, 2006, Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas, NMR Biomed., 19, 463, 10.1002/nbm.1059 · DOI
  16. Ceroni, 2008, GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans, J. Proteome Res., 7, 1650, 10.1021/pr7008252 · DOI · Paper page
  17. Colonna, 1997, A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells, J. Exp. Med., 186, 1809, 10.1084/jem.186.11.1809 · DOI · Paper page
  18. Contreras, 2012, Molecular recognition of a single sphingolipid species by a protein’s transmembrane domain, Nature, 481, 525, 10.1038/nature10742 · DOI · Paper page
  19. Cooper, 2001, GlycoMod—a software tool for determining glycosylation compositions from mass spectrometric data, Proteomics, 1, 340, 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B · DOI · Paper page
  20. Cosman, 1997, A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules, Immunity, 7, 273, 10.1016/S1074-7613(00)80529-4 · DOI · Paper page
  21. D’Angelo, 2013, Glycosphingolipids: synthesis and functions, FEBS J., 280, 6338, 10.1111/febs.12559 · DOI · Paper page
  22. Davis, 2015, Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins, Cell Rep., 11, 1727, 10.1016/j.celrep.2015.05.026 · DOI
  23. de Groot, 2016, Complex MHC Class I Gene Transcription Profiles and Their Functional Impact in Orangutans, J. Immunol., 196, 750, 10.4049/jimmunol.1500820 · doi:10.4049/jimmunol.1500820
  24. de Waard, 2020, PAKC: A novel Panel of HLA class I Antigen presentation machinery Knockout Cells from the same genetic origin, Eur. J. Immunol., 10.1101/2020.01.24.917807 · doi:10.1101/2020.01.24.917807
  25. Dersh, 2020, Genome-wide Screens Identify Lineage- and TumorSpecific Genes Modulating MHC-I- and MHC-IIRestricted Immunosurveillance of Human Lymphomas, Immunity
  26. Desai, 2000, Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains, J. Immunol., 165, 3275, 10.4049/jimmunol.165.6.3275 · DOI
  27. Domon, 1988, Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry, Biochemistry, 27, 1534, 10.1021/bi00405a021 · doi:10.1021/bi00405a021
  28. Duquesnoy, 2013, Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays, Hum. Immunol., 74, 1271, 10.1016/j.humimm.2013.05.016 · DOI
  29. Duquesnoy, 2012, Structural aspects of human leukocyte antigen class I epitopes detected by human monoclonal antibodies, Hum. Immunol., 73, 267, 10.1016/j.humimm.2011.11.011 · DOI
  30. Fantini, 2000, Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion, Glycoconj. J., 17, 199, 10.1023/A:1026537122903 · DOI
  31. Fluhrer, 2007, Signal peptide peptidases and gamma-secretase: cousins of the same protease family?, Neurodegener. Dis., 4, 112, 10.1159/000101835 · DOI
  32. Fröhlich, 2015, The GARP complex is required for cellular sphingolipid homeostasis, eLife, 4, e08712, 10.7554/eLife.08712 · DOI · Paper page
  33. Furukawa, 2015, Comprehensive Glycomics of a Multistep Human Brain Tumor Model Reveals Specific Glycosylation Patterns Related to Malignancy, PLoS ONE, 10, e0128300, 10.1371/journal.pone.0128300 · DOI
  34. Gao, 1997, Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2, Nature, 387, 630, 10.1038/42523 · DOI · Paper page
  35. Gao, 2009, Accurate detection and complete tracking of large populations of features in three dimensions, Opt. Express, 17, 4685, 10.1364/OE.17.004685 · DOI · Paper page
  36. Garstka, 2015, The first step of peptide selection in antigen presentation by MHC class I molecules, Proc. Natl. Acad. Sci. USA, 112, 1505, 10.1073/pnas.1416543112 · DOI
  37. Ghisaidoobe, 2014, Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors, J. Med. Chem., 57, 9096, 10.1021/jm501181z · DOI
  38. Gonen-Gross, 2010, Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface, PLoS ONE, 5, e8941, 10.1371/journal.pone.0008941 · DOI
  39. Griffioen, 2012, Identification of 4 novel HLA-B∗40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity, Haematologica, 97, 1196, 10.3324/haematol.2011.049478 · doi:10.3324/haematol.2011.049478
  40. Hähnel, 2008, Targeting AKT signaling sensitizes cancer to cellular immunotherapy, Cancer Res., 68, 3899, 10.1158/0008-5472.CAN-07-6286 · DOI · Paper page
  41. Hakomori, 1984, Tumor-associated carbohydrate antigens, Annu. Rev. Immunol., 2, 103, 10.1146/annurev.iy.02.040184.000535 · doi:10.1146/annurev.iy.02.040184.000535 · Paper page
  42. Hansen, 2009, MHC class I antigen presentation: learning from viral evasion strategies, Nat. Rev. Immunol., 9, 503, 10.1038/nri2575 · DOI · Paper page
  43. Haworth, 2015, Going back to class I: MHC and immunotherapies for childhood cancer, Pediatr. Blood Cancer, 62, 571, 10.1002/pbc.25359 · DOI
  44. Hiby, 2010, Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2, J. Clin. Invest., 120, 4102, 10.1172/JCI43998 · DOI · Paper page
  45. Hogan, 1992, Localization and characterization of serologic epitopes on HLA-A2, Hum. Immunol., 33, 185, 10.1016/0198-8859(92)90070-4 · doi:10.1016/0198-8859(92)90070-4
  46. Jensen, 2012, Structural analysis of N- and O-glycans released from glycoproteins, Nat. Protoc., 7, 1299, 10.1038/nprot.2012.063 · DOI · Paper page
  47. Jongsma, 2019, The regulatory network behind MHC class I expression, Mol. Immunol., 113, 16, 10.1016/j.molimm.2017.12.005 · DOI · Paper page
  48. Karlsson, 2004, Negative ion graphitised carbon nano-liquid chromatography/mass spectrometry increases sensitivity for glycoprotein oligosaccharide analysis, Rapid Commun. Mass Spectrom., 18, 2282, 10.1002/rcm.1626 · DOI
  49. Kingsley, 1986, Three types of low density lipoprotein receptor-deficient mutant have pleiotropic defects in the synthesis of N-linked, O-linked, and lipid-linked carbohydrate chains, J. Cell Biol., 102, 1576, 10.1083/jcb.102.5.1576 · DOI · Paper page
  50. Kuhn, 2015, Secretome analysis identifies novel signal Peptide peptidase-like 3 (Sppl3) substrates and reveals a role of Sppl3 in multiple Golgi glycosylation pathways, Mol. Cell. Proteomics, 14, 1584, 10.1074/mcp.M115.048298 · DOI · Paper page
  51. Lachmann, 2003, Miglustat. Oxford GlycoSciences/Actelion, Curr. Opin. Investig. Drugs, 4, 472
  52. Ladasky, 1999, Residue 3 of beta2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody, Immunogenetics, 49, 312, 10.1007/s002510050498 · doi:10.1007/s002510050498
  53. Li, 2012, Crystal structure of adenovirus E3-19K bound to HLA-A2 reveals mechanism for immunomodulation, Nat. Struct. Mol. Biol., 19, 1176, 10.1038/nsmb.2396 · DOI
  54. Liu, 2013, Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance, Adv. Cancer Res., 117, 59, 10.1016/B978-0-12-394274-6.00003-0 · DOI · Paper page
  55. Logtenberg, 2019, Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy, Nat. Med., 25, 612, 10.1038/s41591-019-0356-z · DOI · Paper page
  56. Marrari, 2010, Human monoclonal antibody reactivity with human leukocyte antigen class I epitopes defined by pairs of mismatched eplets and self-eplets, Transplantation, 90, 1468, 10.1097/TP.0b013e3182007b74 · doi:10.1097/tp.0b013e3182007b74
  57. Merrill, 2017, Opinion article on lipidomics: Inherent challenges of lipidomic analysis of sphingolipids, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1862, 774, 10.1016/j.bbalip.2017.01.009 · DOI
  58. Miller-Podraza, 1993, New method for the isolation of polyglycosylceramides from human erythrocyte membranes, Biochim. Biophys. Acta, 1168, 330, 10.1016/0005-2760(93)90190-K · doi:10.1016/0005-2760(93)90190-k
  59. Miller-Podraza, 1997, Screening for the presence of polyglycosylceramides in various tissues: partial characterization of blood group-active complex glycosphingolipids of rabbit and dog small intestines, Glycoconj. J., 14, 231, 10.1023/A:1018545922728 · DOI
  60. Mitra, 2004, Supine orientation of a murine MHC class I molecule on the membrane bilayer, Curr. Biol., 14, 718, 10.1016/j.cub.2004.04.004 · DOI
  61. Moesta, 2008, Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3, J. Immunol., 180, 3969, 10.4049/jimmunol.180.6.3969 · DOI · Paper page
  62. Moore, 2008, Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection, Viral Immunol., 21, 327, 10.1089/vim.2008.0003 · doi:10.1089/vim.2008.0003
  63. Mulder, 2010, Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation, Mol. Immunol., 47, 809, 10.1016/j.molimm.2009.10.004 · DOI
  64. Neefjes, 1990, N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response, J. Exp. Med., 171, 583, 10.1084/jem.171.2.583 · DOI
  65. Ogretmen, 2004, Biologically active sphingolipids in cancer pathogenesis and treatment, Nat. Rev. Cancer, 4, 604, 10.1038/nrc1411 · DOI · Paper page
  66. Oostvogels, 2014, Identification of minor histocompatibility antigens based on the 1000 Genomes Project, Haematologica, 99, 1854, 10.3324/haematol.2014.109801 · DOI
  67. Ovesný, 2014, ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging, Bioinformatics, 30, 2389, 10.1093/bioinformatics/btu202 · DOI · Paper page
  68. Pech, 2019, Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance, eLife, 8, e47362, 10.7554/eLife.47362 · DOI
  69. Platt, 1994, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J. Biol. Chem., 269, 8362, 10.1016/S0021-9258(17)37202-2 · DOI · Paper page
  70. Plomp, 2014, Site-specific N-glycosylation analysis of human immunoglobulin e, J. Proteome Res., 13, 536, 10.1021/pr400714w · DOI
  71. Potapenko, 2015, Glycan-related gene expression signatures in breast cancer subtypes; relation to survival, Mol. Oncol., 9, 861, 10.1016/j.molonc.2014.12.013 · DOI
  72. Purbhoo, 2004, T cell killing does not require the formation of a stable mature immunological synapse, Nat. Immunol., 5, 524, 10.1038/ni1058 · DOI · Paper page
  73. Radsak, 1984, Glycosphingolipid synthesis in human fibroblasts infected by cytomegalovirus, Virology, 138, 300, 10.1016/0042-6822(84)90353-2 · doi:10.1016/0042-6822(84)90353-2
  74. Reiser, 2014, Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans, J. Immunol., 193, 5816, 10.4049/jimmunol.1303084 · DOI
  75. Restifo, 1996, Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy, J. Natl. Cancer Inst., 88, 100, 10.1093/jnci/88.2.100 · DOI · Paper page
  76. Rigau, 2020, Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells, Science, 367, eaay5516, 10.1126/science.aay5516 · DOI · Paper page
  77. Righi, 2009, 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas, NMR Biomed., 22, 629, 10.1002/nbm.1377 · DOI
  78. Rocha, 2009, Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning, J Cell Biol, 185, 1209, 10.1083/jcb.200811005 · DOI · Paper page
  79. Roszkowski, 2003, CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell, J. Immunol., 170, 2582, 10.4049/jimmunol.170.5.2582 · DOI
  80. Ryan, 2012, Roles for major histocompatibility complex glycosylation in immune function, Semin. Immunopathol., 34, 425, 10.1007/s00281-012-0309-9 · DOI
  81. Saverino, 2000, The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions, J. Immunol., 165, 3742, 10.4049/jimmunol.165.7.3742 · DOI · Paper page
  82. Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 · DOI · Paper page
  83. Schütz, 1997, Single-molecule microscopy on model membranes reveals anomalous diffusion, Biophys. J., 73, 1073, 10.1016/S0006-3495(97)78139-6 · DOI · Paper page
  84. Shayman, 2010, ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease, Drugs Future, 35, 613, 10.1358/dof.2010.35.8.1505566 · DOI
  85. Shi, 2011, Plasticity of human CD8αα binding to peptide-HLA-A∗2402, Mol. Immunol., 48, 2198, 10.1016/j.molimm.2011.05.009 · doi:10.1016/j.molimm.2011.05.009
  86. Spaapen, 2008, Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis, J. Exp. Med., 205, 2863, 10.1084/jem.20080713 · DOI
  87. Stirnemann, 2017, A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments, Int. J. Mol. Sci., 18, 441, 10.3390/ijms18020441 · DOI · Paper page
  88. Taketani, 1983, Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant, J. Immunol., 131, 2935, 10.4049/jimmunol.131.6.2935 · DOI
  89. Thor Straten, 2016, Targetless T cells in cancer immunotherapy, J. Immunother. Cancer, 4, 23, 10.1186/s40425-016-0127-z · DOI
  90. Trymbulak, 1997, Mutants of human beta2-microglobulin map an immunodominant epitope within the three-stranded beta-pleated sheet, Transplantation, 64, 640, 10.1097/00007890-199708270-00016 · doi:10.1097/00007890-199708270-00016
  91. Unanue, 1989, Antigen presentation, FASEB J., 3, 2496, 10.1096/fasebj.3.13.2572499 · doi:10.1096/fasebj.3.13.2572499
  92. Valiante, 1997, Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors, Immunity, 7, 739, 10.1016/S1074-7613(00)80393-3 · DOI · Paper page
  93. van Bergen, 2007, Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene, Blood, 109, 4089, 10.1182/blood-2006-08-043935 · DOI
  94. Van Bergen, 2010, High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning, Cancer Res., 70, 9073, 10.1158/0008-5472.CAN-10-1832 · DOI
  95. Voss, 2012, Foamy virus envelope protein is a substrate for signal peptide peptidase-like 3 (SPPL3), J. Biol. Chem., 287, 43401, 10.1074/jbc.M112.371369 · DOI
  96. Voss, 2014, Shedding of glycan-modifying enzymes by signal peptide peptidase-like 3 (SPPL3) regulates cellular N-glycosylation, EMBO J., 33, 2890, 10.15252/embj.201488375 · DOI · Paper page
  97. Voss, 2013, Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases, Biochim. Biophys. Acta, 1828, 2828, 10.1016/j.bbamem.2013.03.033 · DOI
  98. Wang, 2012, High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients, Glycobiology, 22, 930, 10.1093/glycob/cws061 · DOI
  99. Wearsch, 2008, The quality control of MHC class I peptide loading, Curr. Opin. Cell Biol., 20, 624, 10.1016/j.ceb.2008.09.005 · DOI · Paper page
  100. Wieser, 2007, (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy, Biophys. J., 92, 3719, 10.1529/biophysj.106.095398 · DOI
  101. Wikstrand, 1991, Occurrence of lacto series gangliosides 3′-isoLM1 and 3′,6′-isoLD1 in human gliomas in vitro and in vivo, J. Neuropathol. Exp. Neurol., 50, 756, 10.1097/00005072-199111000-00007 · doi:10.1097/00005072-199111000-00007
  102. Willcox, 2003, Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor, Nat. Immunol., 4, 913, 10.1038/ni961 · DOI · Paper page
  103. Wraith, 2009, New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat, Ther. Clin. Risk Manag., 5, 877, 10.2147/TCRM.S5777 · DOI · Paper page
  104. Yewdell, 2002, Viral interference with antigen presentation, Nat. Immunol., 3, 1019, 10.1038/ni1102-1019 · DOI · Paper page
  105. Zhang, 2019, The Role of Glycosphingolipids in Immune Cell Functions, Front. Immunol., 10, 90, 10.3389/fimmu.2019.00090 · DOI · Paper page
  106. Zhang, 2020, The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I, bioRxiv

Cited by

See all 108

Metadata

Authors
Jongsma, M. L. M., de Waard, A. A., Raaben, M., Zhang, T., Cabukusta, B., Platzer, R., Blomen, V. A., Xagara, A., Verkerk, T., Bliss, S., Kong, X., Gerke, C., Janssen, L., Stickel, E., Holst, S., Plomp, R., Mulder, A., Ferrone, S., Claas, F. H. J., Heemskerk, M. H. M., Griffioen, M., Halenius, A., Overkleeft, H., Huppa, J. B., Wuhrer, M., Brummelkamp, T. R., Neefjes, J., & Spaapen, R. M.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-01
Volume
54
Issue
1
Pages
132-150.e9
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3106908673
Cited by
108
References
19
FWCI
3.73
Type
journal article
Language
en
Update notices
erratum (2021-02-09)
Open access
bronze
Licence
Funders
  • Vienna Science and Technology Fund (LS14-031)
  • U.S. Department of Defense (W81XWMH-16-1-0500)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (ZonMw-ETH 435004024)
  • Landsteiner Foundation for Blood Transfusion Research (1842F)
  • Boehringer Ingelheim Fonds
  • Cancer Genomics Centre
  • European Molecular Biology Organization (ASTF 10-2016)
  • KWF Kankerbestrijding (2015-7982, NKI2015-7609)
  • National Institutes of Health (R01DE028172, RO3CA223886, RO3CA231766, R03CA216114)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.